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Abstract
In recent years, the number of studies using a cluster-randomized design has grown dramatically. In addition, the cluster-
randomized crossover design has been touted as a methodological advance that can increase efficiency of cluster-
randomized studies in certain situations. While the cluster-randomized crossover trial has become a popular tool, standards
of design, analysis, reporting and implementation have not been established for this emergent design. We address one
particular aspect of cluster-randomized and cluster-randomized crossover trial design: estimating statistical power. We
present a general framework for estimating power via simulation in cluster-randomized studies with or without one or more
crossover periods. We have implemented this framework in the clusterPower software package for R, freely available online
from the Comprehensive R Archive Network. Our simulation framework is easy to implement and users may customize the
methods used for data analysis. We give four examples of using the software in practice. The clusterPower package could
play an important role in the design of future cluster-randomized and cluster-randomized crossover studies. This work is the
first to establish a universal method for calculating power for both cluster-randomized and cluster-randomized clinical trials.
More research is needed to develop standardized and recommended methodology for cluster-randomized crossover
studies.
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Introduction
Clinical trials are often designed to assess the effectiveness of a
particular intervention. While evidence from individually-ran-
domized, masked clinical trials is considered the gold standard of
scientific evidence, in many settings, such a design is not feasible
and, sometimes, is unethical. Cluster-randomized trials randomize
groups of people instead of individuals. These studies can be
valuable tools for evaluating interventions that are best imple-
mented at the group level. Some have argued that a cluster-
randomized design yields more accurate estimates of the treatment
effect of interest because the treatment effect is estimated on the
level at which the intervention is applied [1]. Looking forward,
cluster-randomized designs will continue to play an important role
in clinical effectiveness research, filling in when individually
randomized studies are not possible.
Many questions remain about best practices for cluster-
randomized studies. A variant to the cluster-randomized study
design, the cluster-randomized crossover design, has been touted
as a methodological advance that can increase efficiency of cluster-
randomized studies in certain situations. While the cluster-
randomized crossover trial has become a popular tool, standards
of design, analysis, reporting and implementation have not been
established for this emergent design. This is largely due to the fact
that the principles from cluster-randomized trials with no
crossover are not easily applied to a crossover setting. The
crossover introduces a significant paradigm change in analyzing
cluster-randomized data. In a cluster-randomized crossover trial,
statistical inference is based on evidence drawn from within-cluster
comparisons. In standard cluster-randomized trials, between-
cluster comparisons provide the evidence. Therefore, techniques
for analyzing data from cluster-randomized crossover trials are
very different from those used to analyze data from cluster-
randomized trials with no crossover.
In this paper, we discuss a single aspect of designing cluster-
randomized and cluster-randomized crossover trials: estimating
statistical power. Many scientific studies set out to gather evidence
that can be used to evaluate a specific hypothesis. An investigator
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study will produce definitive evidence for or against a hypothesis.
Statistical power is defined as the probability of correctly rejecting
the null hypothesis, or phrased another way, the probability of
having conclusive evidence for one hypothesis over another given
the existing study design. Accurate power calculations provide
guidance for the appropriate sample-size requirement for a given
study. Obtaining an accurate estimate of the necessary sample size
to answer a given scientific question in a particular setting ensures
that researchers do not enroll too few or too many participants in a
study. These calculations, a vital part of any thorough study
proposal, can be complicated in cluster-randomized settings
because of the correlation structures that are often present within
clustered data.
Methods for calculating power for cluster-randomized trials
exist in patchwork, with investigators having to hunt for the
method or equation that fits their specific needs. Formulas do exist
to calculate power for cluster-randomized trials with continuous or
dichotomous outcomes [2] or for cluster-randomized trials with
continuous, dichotomous or categorial outcomes [3], however they
cannot easily be generalized to incorporate a crossover period.
Methods to analyze cluster-randomized crossover trials with
continuous or dichotomous outcomes have been proposed [4–6],
as have methods for calculating power in cluster-randomized
crossover settings with continuous outcome data [7]. Although
these methods have been developed for specific cluster-random-
ized designs, no unified framework has enabled power calculations
in both cluster-randomized and cluster-randomized crossover
settings. We present such a framework which enables apples-to-
apples comparisons between the two study designs and can be
important for an investigator wishing to compare the efficiency of
the two designs.
For complex study designs, such as the cluster-randomized
crossover, simple formulas to calculate power may not adequately
capture the expected variability from observed data. In these cases,
estimation of power via simulation methods may be needed [8].
Simulation methods have the added advantage of being able to
work in a wide range of settings, both simple and complex. This
can facilitate comparisons between study designs, such as those
presented in Example D, below. We present a unifying data
generating model for continuous, dichotomous or count outcome
data from a cluster-randomized study – with or without one or
more crossover periods. This framework is implemented in the
clusterPower software package for R, which has been designed to
run simulated power calculations. We simulate an empirical
estimate of the power that can be used by researchers in the study
design phase. This tool is, to our knowledge, the only freely
available tool that can calculate power for a wide range of
standard cluster-randomized and cluster-randomized crossover
study designs.
In the following Methods section we present our software tool
and discuss the underlying data generating model. In the Results
section we give three examples of the tool in practice. In the
Discussion section we address possible limitations and extensions
of this work.
Methods
Overview
Simulation is a powerful tool for estimating the power of a
complex study when the data analysis procedure is not straight-
forward (see, for example, [9], p. 176 or [10]). Indeed, one paper
has discussed the idea of simulation of power for cluster-
randomized trials, although only in the context of continuous
data [11]. The idea is to randomly generate numerous datasets,
each of which represents a hypothetical version of the study to be
conducted. The datasets are generated assuming that a specific
alternative hypothesis is true. The null hypothesis is that a
treatment has no effect (H0 : b~0) and the alternative is that the
treatment has an effect (HA : b~bA=0): As with other types of
power calculations, a specific alternative treatment effect is
specified – for example, bA could equal 2 – and datasets are
generated from the resulting model. For each of these datasets, the
data analysis is carried out and the evidence for or against the null
hypothesis is recorded. A Type-I error rate, commonly referred to
as a, is the probability of rejecting a null hypothesis when the null
hypothesis is actually true. Typically, biomedical researchers set an
acceptable a-level at 1 in 20, or 0.05. In our example, if 1000
datasets are generated and in 800 of them the null hypothesis is
correctly rejected (i.e. the p-value is less than a), then we would
estimate an empirical power of 800/1000 or 80%.
We have developed free software, the clusterPower package for
R, which generates simulated datasets as described above and
analyzes each dataset using a particular statistical method which
can be customized for the situation [12,13]. The clusterPower
package can be downloaded for free from the Central R Archive
Network (CRAN) or from github, a popular code collaboration
site. In addition, making the source code available on github
allows for anyone with necessary skills and interest to offer
additions and/or improvements to the existing package. The
functions power.sim.normal(), power.sim.binomial() and power.-
sim.poisson() return the estimates of treatment effect as well as the
empirical power estimate for the particular parameter combina-
tion used to simulate the data. To our knowledge, no other free
software is available to calculate power for cluster-randomized
crossover trials with all of these three types of outcome data.
Data Generating Model
We have a study with K clusters, J study periods and Njk
participants in the kth cluster and the jth period. We define Yijk as
the random variable representing the outcome of interest for the ith
individual in the kth cluster during the jth period of the study. The
treatment assignments will vary by cluster and period. Therefore,
we will use a separate indicator variable, Xjk to indicate whether
cluster k during period j is assigned to the treatment arm (Xjk~1)
or the control arm (Xjk~0): Cluster-randomized trials with no
crossover will be treated as the subset of cluster-randomized
crossover trials that have a single period of study. We assume a
generalized linear mixed model (GLMM) framework of
g E½Yijkjp,a,b 

~pjzakzb:Xjk ð1Þ
where pj are fixed period effects, b is the fixed treatment effect and
the ak are random cluster effects following a normal distribution
N(0,s2
a).
This is a cluster-level model, as no individual-level character-
istics appear as predictors or covariates in equation 1. In the design
phase of a cluster-randomized crossover trial, it is common
practice to power a study based on adjustment for only cluster-
level variables, ignoring individual-level variability in covariates.
Equation 1 is an example of such a model. It accounts for cluster-
level correlation but does not introduce individual-level covari-
ates – keeping the model at a manageable level of complexity for a
simulation-based power calculation. We will consider parametric
GLMMs for continuous, binary and count outcome data.
The overall goal is to simulate data from the general model so
that an empirical power calculation can be run. Some of the data-
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are not. The following subsections outline the other specific
information needed to generate individual-level data from these
models for analysis. Table 1 summarizes the parameters used in the
data generating model, translating between the the notation used in
this manuscript and the R code needed for implementation.
Continuous outcome data. Continuous outcome data will
be generated using a Gaussian or normal GLMM, also known as a
linear mixed model. In this setting, Yijk is assumed to be a
continuously measured outcome variable. This model will be of
the form
YijkjXjk~pjzakzb:XjkzEijk
Eijk*Normal(0,s2
E)
ak*Normal(0,s2
a):
ð2Þ
Data can be simulated from this model by specifying the fixed
effects (b and pj) and distributions for the random effects. The
outcome is modeled on the same scale as the predictor function, so
the fixed effects are specified on the same scale as the outcome
measurements. If we define the intraclass correlation coefficient
ICC=
s2
a
s2
azs2
E
, then specifying two of the three parameters (ICC,
s2
a, ) is sufficient to simulate observations from the model.
Binary outcome data. Binary data will be generated using a
logistic GLMM. Here, Yijk~0 or 1, depending on how the binary
outcome is defined. We model the probability of the outcome as
logit E YijkjXjk

~pjzakzb:Xjk ð3Þ
ak*Normal(0,s2
a):
By assuming values for the fixed effects and specifying the
variance of the random cluster effects, s2
a, we can simulate data
from this model. Care must be taken in specifying the variance,
and input from experts and/or past studies is vital.
Poisson outcome data. Count data will be generated using a
log-linear Poisson GLMM. In this setting, Yijk is assumed to be a
non-negative integer and Tijk is the at risk time for person i in
group k during period j. This model will be of the form
logE½YijkjTijk,Xjk ~logTijkzpjzakzb:Xjk ð4Þ
ak*Normal(0,s2
a):
By assuming values for the fixed effects and specifying the
variance of the random cluster effects, s2
a, we can simulate data
from this model. Care must be taken in specifying an appropriate
variance, and input from experts and/or past studies is vital. For
simple power calculations, one may assume Tijk to be the same
for all individuals. However, we can simulate different at-risk
times for participants by specifying parameters for a negative
binomial distribution. For example, we can assume that
Tijk*NegativeBinomial(m,k) where the mean of this distribution
is m and the variance is mzm2=k. In this parameterization the
parameter k is referred to as the size or dispersion of the
distribution. Using this formulation for exposure times allows the
researcher to adjust the variability in the exposure times to fit
the application of interest.
Results
This section presents three examples of the clusterPower
package. The R code for all examples is available as Code S1.
Example A: A Cluster-randomized Crossover Trial with No
Period Effect
We developed this hypothetical example of a power calculation
based on our experience with the Pediatric SCRUB clinical trial, a
multi-center, cluster-randomized crossover trial. A nested study
from the SCRUB trial has been described elsewhere [14]. This
trial aims to evaluate the effectiveness of daily clorhexidine
gluconate (CHG) bathing in pediatric intensive care units (PICUs)
to reduce blood-stream infections. The actual study design and
analysis plan differed slightly from what we present here, which we
have simplified for the purposes of illustration. Ten PICUs
participated in this study. Subsequently, each PICU participated
for two six-month study periods separated by a two-week washout
period. Five PICUs were randomly chosen to receive CHG
treatment in the first time period and standard of care in the
second. The other five were assigned the reverse treatment
ordering: first standard of care, then CHG. For the duration of the
entire study, active surveillance registered blood-stream infection
events and each enrolled patient’s time at risk was recorded.
We used equation 4 to simulate data from hypothetical
realizations of this trial. Each cluster-period had 210 participants
and each participant was assumed to have 10 at-risk days. In
reality the at-risk days vary widely by individual. However our
calculations were aggregated at the cluster level since we assume
that there are no individual-level risk factors. Therefore, we
assumed that each cluster accumulates 2100 at-risk days per
period, or over 300 at-risk days per month. This was roughly in
line with observed data from the pilot and study period.
Further, we assumed that the baseline risk of blood-stream
infection was 4 infections per 1000 person at-risk days and did not
change with study period, i.e. pj~p~log0:004 for all j. The
treatment was assumed to reduce the risk of blood-stream infection
Table 1. Parameters from data generating models needed to
simulate power.
notation text outcome data type
continuous binary count
K n.clusters 33 3
J n.periods 33 3
Njk clust.size 33 3
pj, sp period.effecta, period.var b 33 3
b effect.size 33 3
s2
a btw.clust.var 33 3
s2
E indiv.varc 3
ICC ICCc 3
Tijk at.risk.params 3
aThe period effects are drawn from a normal distribution centered at
period.effect with variance period.var.
bIf period.var=0, then period.effect is assumed to be the same for all periods.
cOnly one of the ICC and needs to be specified in continuous data generating
models.
doi:10.1371/journal.pone.0035564.t001
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Therefore, we set b~log(0:75). For each dataset, a1,...,a10
were drawn from a normal distribution centered at zero with
variance s2
a. The baseline incidence rate and variance were
specified with input from clinical experts and by consulting past
published data [15]. We chose the variance (with precision to the
nearest tenth of a decimal place) so that 9 out of every 10 clusters
would have infection rates below 10 infections per 1000 at-risk
days. For our primary power calculation, s2
a~0:5 met this criteria.
We used a fixed effects Poisson regression model to draw
inference about the treatment effect. The model was fit to the 20
datapoints (two observations for each of ten units). In this approach,
inference was drawn about the parameter b based on whether the
95% confidence interval covered zero; if the confidence interval
covered zero then we failed to reject the null hypothesis.
For the fixed effects Poisson regression model, we assumed
that
logE½YjkjTjk,Xjk ~logTjkzakzb:Xjk
where b is an estimate of the treatment effect and the ak are
cluster-specific parameters for k~1,...,10: In this model, we
have J   K~2   10~20 observations, and we fit Kz1~11
parameters. The logTjk are used as an offset.
For this example, power may be calculated using the power.-
sim.poisson() function in the clusterPower package for the
statistical software R using a single command. The lines of code
below demonstrate how the package may be freely downloaded
and installed from the internet, loaded into the a working R
environment, and run. The set.seed(17) command sets the random
seed to a fixed number, ensuring that the results shown here are
reproducible.
.install.packages(‘‘clusterPower’’)
.library(clusterPower)
.set.seed(17)
.p,-power.sim.poisson(n.sim=1000, effect.size=log(.75),
alpha=.05,
n.clusters=10, n.periods=2,
cluster.size=210,
btw.clust.var=.5, at.risk.params=10,
period.effect=log(.004), period.var=0,
estimation.function=fixed.effect.cluster.
level)
.p$power
[1] 0.508
Full documentation of the power.sim.poisson() command is
available online and in the help files within R.
Table 2 shows one of the simulated datasets, including the crude
estimates of the incidence rate ratio within each cluster. The
results of our power simulation example, which simulated 1000
such datasets, show that in this setting there is just over 50% power
to detect a 25% reduction in the relative risk of infection due to the
CHG intervention.
Additionally, this one-off power calculation could be supple-
mented with an exploration of power as different parameters – for
example, the number of clusters, overall sample size or between-
cluster variability – change. To illustrate such a use, we simulated
power for our study across a range of cluster-sizes while keeping
our earlier assumptions. Figure 1 shows that to achieve 80% power
in a study with 210 participants per cluster-period, 22 clusters
would be needed. These types of additional simulations can give
more insight into the appropriate study design and can inform a
final authoritative power calculation.
Example B: A Cluster-randomized Crossover Clinical Trial
with Time-varying Prevalence
We extend the previous example to incorporate time-varying
incidence rates of blood-stream infections. Here, we assume that the
background incidence rate of blood-stream infections is decreasing
over time. In the first period of the study we assume that the
background rate is 4 infections per 1000 person at-risk days and in
the second period we assume that it is 3 infections per 1000 person
at-risk days. We fit a model that includes a fixed period effect, so our
estimate of the treatment effect is adjusted for this secular trend.
In this scenario, 24 clusters are needed to obtain 80% power.
This is two more than the 22 needed in the scenario with a fixed
background rate. Figure 1 compares the simulated power of the
two scenarios, and we observe a clear and quantifiable drop in
power when the time-varying period effect is included. Code to
reproduce example B is available in the Code S1.
Example C: A Cluster-randomized Incentive Trial
We now present a power calculation for a proposed trial of
incentives to improve medication adherence. In this trial,
investigators are collaborating with a large pharmacy benefits
provider to randomize patients to either a new benefit design
(including reduced co-pays) or control. Due to ethical and trial
considerations, randomization must take place at the employer
health plan level. The number of employer health plans available
to be randomized is fixed at 8, but we may control the size of the
sample within each employer. The outcome, adherence to a
prescribed preventive cardiovascular medication, will be measured
as a binary variable for each patient. We expect the adherence rate
in the control group to be approximately 50% and the variation in
adherence rates across clusters to be very small (s2
a~0:005):
We considered power under varying effect sizes (differences in
adherence between intervention and control arms of 0.06, 0.08, and
0.1). We also varied the number of patients sampled per cluster. We
used the power.sim.binom() function to simulate 500 datasets for
each set of parameter values. Because the number of clusters is low,
power was calculated assuming that a simple fixed effects logistic
regression model will be applied for data analysis. Figure 2 shows
the power calculated under all parameter values withsample sizeon
the x-axis and lines connecting data points calculated under the
same effect size. Under a true difference in adherence of only 6%, a
Table 2. One of the 1000 Simulated data sets.
number of events
unit control treatment IRRa
1 14 10 0.71
2 17 7 0.41
3 8 3 0.38
4 6 4 0.67
5 11 5 0.45
6 20 7 0.35
7 12 15 1.25
8 5 5 1.00
9 4 4 1.00
10 9 8 0.89
aThe incidence rate ratio (IRR) is the number of treatment events divided by the
number of control events.
doi:10.1371/journal.pone.0035564.t002
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considered. If the effect size is 8% or larger, then 1000 patients per
cluster will be sufficient to achieve 80% power. Code to reproduce
example C is available in the Code S1.
Example D: A Clinical-effectivenes Cluster-randomized
Crossover Trial
Hejblum et al. (2009) conducted a cluster-randomized crossover
trial in 21 intensive care units in France to examine the change in
the number of chest radiographs taken when comparing the status
quo to a new on-demand strategy for ordering the radiographs.
The results in the paper suggest that the on-demand strategy for
ordering chest radiographs could significantly reduce the number
of chest radiographs taken without impacting quality of care. To
show the value the crossover design provides to a study such as this
one, we calculated power for two hypothetical cluster-randomized
studies – one with a crossover and one without – that attempt to
replicate the findings of Hejblum et al.
We assumed that the average amount of time a patient spent on
mechanical ventilation was 5 days. Also based on the published data,
we assumed that an average of 1 chest radiographs per day were taken
while on mechanical ventilation in the status quo group. We ran these
calculations, assuming a type-I error rate of 5% and assuming a
between-cluster variance of 0.01 (chest-radiographs per day)
2.T h e
code to run this analysis is given below:
.n.clusters ,-20
.size ,-20
.nsim ,-1000
.bcv ,-.01
.at.risk ,-5
.baseline ,-1
.exD.crxo ,-power.sim.poisson(n.sim=nsim, effect.size=log(.9),
alpha=.05,
n.clusters=n.clusters, n.periods
=2,
cluster.size=size, btw.clust.var=
bcv,
at.risk.params=at.risk,
verbose=FALSE,
period.effect=log(baseline),
period.var=0,
estimation.function=fixed.
effect.cluster.level)
. exD.crxo$power
[1] 0.912
.exD.cr ,2power.sim.poisson(n.sim=nsim, effect.size=log(.
9), alpha=.05,
n.clusters=n.clusters, n.periods
=1, cluster.size=size*2,
btw.clust.var=bcv, at.risk.params
=at.risk, verbose=FALSE,
period.effect=log(baseline),
period.var=0,
estimation.function=fixed.
effect.cluster.level)
.exD.cr$power
[1] 0.336
Figure 1. Power curves from Examples A and B. These curves show the relationship of power with the number of clusters. The points show simulated
power for 1000 datasets with a smoothed line drawn through the data to highlight the overall pattern. The solid line and gray points represent the simulations
with constant baseline rates (Example A) and the open circles and dashed line represent the simulations with time-varying baseline rates (Example B).
doi:10.1371/journal.pone.0035564.g001
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clusters of 20 participants in each period (800 participants total),
the study would have 91.2% power to detect a 10% reduction in
the number of chest radiographs ordered. For the hypothetical
cluster-randomized study with 20 clusters and 40 participants in
each cluster (and no crossover period) we would have only 33.6%
power to detect the same 10% reduction. We see that in a study
such as this, the crossover design plays a crucial role in making a
study viable.
Discussion
This manuscript introduces a practical and freely-available tool
for researchers to run power calculations for cluster-randomized
and cluster-randomized crossover studies. By providing a stan-
dardized platform for calculating power for these types of studies,
this tool – the clusterPower package for R – enables comparisons
between the two types of designs and may aid researchers in
developing efficient study protocols. Cluster-randomized studies
have become increasingly popular in recent years. In fields such as
hospital epidemiology and educational research, they are com-
monplace. The benefits and drawbacks to a cluster-randomized
design are increasingly being discussed [1,16,17]. However, as
this design and its derivatives (such as the cluster-randomized
crossover design) become more widely used, a more thorough
understanding of optimal settings for these designs is crucial. In
particular, cluster-randomized crossover studies provide a unique
design for evaluating the clinical effectiveness of a particular
intervention.
While our software makes a complicated calculation accessible
and easy to implement, careful attention is required to ensure that
the inputs for the simulator are accurate. Determining the
appropriate between-cluster variance may not be a trivial task,
especially if background data is limited or does not exist.
Furthermore, our software is designed for a general and relatively
simple scenario. Although we expect this design to cover many
common designs, some studies may not fit these pre-packaged
formulas. For studies with design complexities not covered by
these settings, additional programming may be necessary to use
this framework. Using an individual-level framework for simula-
tion would create a more flexible data generation architecture,
allowing for individual-level variability to be simulated. Currently,
this has not been implemented in our framework.
The framework that we introduce in this manuscript creates
opportunities to expand our knowledge about the dynamics of
cluster-randomized studies. For example, increased between-
cluster variability may lead to better or worse power, holding all
other things equal. Similarly, the impact of increased variability of
cluster sizes on power could be explored. Often, statisticians report
a single number as a target enrollment size for all clusters. Power
may change if all clusters had exactly the same size or if clusters
had vastly different sizes. Additionally, the benefit achieved from
adding a crossover to a cluster-randomized design is unknown.
The software described in this manuscript provides a convenient
platform to run tailored simulations to explore all of these
scenarios. As future work, we would like to implement versions of
these functions in other statistical software, like STATA or SAS.
There are some distinct benefits of the simulation framework
presented here in comparison with other methods currently in use.
First, this framework provides a consistent method that can be
applied across a very wide range of cluster-randomized studies.
Common types of outcome data are supported and crossover
Figure 2. Power curves from Example C. These curves depict the relationship between power and sample size per cluster across different effect
sizes. The points show simulated power for 500 datasets.
doi:10.1371/journal.pone.0035564.g002
Power Calculations for Cluster-Randomized Studies
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35564designs are incorporated with ease. Second, the analysis methods
used here – GLMMs – are the methods that are often used in
published analyses. And, if they do not match the statistical
technique that will be used for a given study, our software can be
extended by the end-user with straight-forward programming that
provides a data analysis function with standardized inputs and
outputs.
Some studies may wish for their final data analysis to include
individual-level predictors, especially if some such predictors may
account for a large portion of the variability in the outcome.
However, in crossover studies, the design is explicitly meant to
create balance on these potential confounders, and studies that
have compared cluster- and individual-level analyses of cluster-
randomized crossover studies have shown little difference [6].
While research has been done to determine optimal methods for
analyzing continuous outcome data in cluster-randomized cross-
over trials [5], additional work is needed to establish the best
methods for binary and count data.
As the use of cluster-randomized studies becomes more
common, tools such as the one we introduce and demonstrate in
this manuscript provide practical solutions to often intractable
sample size calculations while furnishing a platform for gaining a
deeper understanding of the dynamics of cluster-randomized and
cluster-randomized crossover trials.
Supporting Information
Code S1 The R code for all examples.
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